Remazin 50 mg

Remazin 50 mg | INDICATIONS AND USES

Diethylcarbamazine is indicated for Filariasis, Lymphatic filariasis, Pulmonary eosinophilia, Loiasis, Toxocariasis.

Remazin 50 mg | PHARMACOLOGY

The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis. One study showed that diethylcarbamazine's activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. It confirmed the important role of the arachidonic acid metabolic pathway in diethylcarbamazine's mechanism of action in vivo and showes that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1.

Remazin 50 mg | DOSAGE & ADMINISTRATION

Inital: 1 mg/kg/day, may increase to 6 mg/kg/day over 3 days, then maintain for 3 wk. Prophylaxis of loiasis 300 mg/wk.

Remazin 50 mg | DRUG INTERACTIONS

There are no known drug interactions and none well documented.

Remazin 50 mg | SIDE EFFECTS

Fever, headache, vomiting, dizziness, drowsiness, nausea, chills.Potentially Fatal: Severe hypersensitivity reactions may occur especially in the treatment of onchocerciasis where rare Mazzotti reaction characterised by rash, itching, headache, muscle and joint pains, tachycardia, postural hypotension may start within 2 hr of drug administration. Encephalitis and retinal haemorrhage.

Remazin 50 mg | USE DURING PREGNANCY AND LACTATION

Pregnancy Category- X. Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Remazin 50 mg | PRECAUTIONS & WARNINGS

Patients with poor health.Lactation: not known if excreted in breast milk

Remazin 50 mg | THERAPEUTIC CLASS

Other Anti-protozoals